Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Vomiting 3 Neoplasms 2 Nausea 2 Solid Tumors 1 Prostatic Neoplasms 1 Polyps 1 Mouth Neoplasms 1 Lymphoma 1 Hypopharyngeal Neoplasms 1 Critical Illness 1 Colonic Neoplasms 1 Breast Neoplasms 1

Interventions

Gemcitabine 9 Paclitaxel 8 Carboplatin 7 atezolizumab 6 Sunitinib 5 navitoclax 4 Topotecan 4 Irinotecan 4 Docetaxel 4 Bevacizumab 4 pazopanib 3 liposomal doxorubicin 3 cobimetinib 3 Nivolumab 3 Erlotinib Hydrochloride 3 zolbetuximab 2 tumor necrosis factor-alpha, CNGRC fusion protein, human 2 temsirolimus 2 selicrelumab 2 plocabulin 2 envafolimab 2 darinaparsin 2 brigimadlin 2 adavosertib 2 Tablets 2 Sorafenib 2 Rifampin 2 RG7388 2 Panitumumab 2 NVP-BKM120 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Solid Tumors × Metoclopramide × Clear all

NCT02135510 2020-03-31

MEDEA

Amsterdam UMC, location VUmc

Phase 3 Completed

Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡